Literature DB >> 2942038

Suppression of rat carotid lesion development by the calcium channel blocker PN 200-110.

D A Handley, R G Van Valen, M K Melden, R N Saunders.   

Abstract

Balloon catheter damage of the rat carotid artery endothelium results in an extensive and reproducible neointimal lesion composed of smooth muscle cells and connective matrix. The authors have examined two calcium channel blockers, PN 200-110 and PY 108-068, for their ability to inhibit neointimal lesion development in the rat carotid model. When given subcutaneously (1.0 mg/kg day) both compounds produced rapidly acting and long-lasting hypotension, reducing blood pressure 25-29%. At this dose given daily, PN 200-110 reduced lesion cross-sectional area by 44%, compared with only 25% seen by PY 108-068, which suggests that the antiatherosclerotic effect may not be related to lowering of blood pressure. Furthermore, PN 200-110 did not reduce the extent of platelet deposition (compared with controls) occurring at the denuded vessel surface 1 hour or 24 hours after balloon catheterization, which indicates that the inhibition of lesion development may not reflect an antiplatelet mechanism. The observed inhibition by PN 200-110 may relate to mitogen responses of the smooth muscle cell in the vessel wall (migration and proliferation) involved in lesion progression after endothelial damage.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2942038      PMCID: PMC1888187     

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  23 in total

1.  Endothelial regeneration in the rat carotid artery and the significance of endothelial denudation in the pathogenesis of myointimal thickening.

Authors:  J A Fishman; G B Ryan; M J Karnovsky
Journal:  Lab Invest       Date:  1975-03       Impact factor: 5.662

Review 2.  The pathogenesis of atherosclerosis (second of two parts).

Authors:  R Ross; J A Glomset
Journal:  N Engl J Med       Date:  1976-08-19       Impact factor: 91.245

3.  A low-viscosity epoxy resin embedding medium for electron microscopy.

Authors:  A R Spurr
Journal:  J Ultrastruct Res       Date:  1969-01

4.  Atherosclerosis: Prevention by agents not affecting abnormal levels of blood lipids.

Authors:  D M Kramsch; A J Aspen; L J Rozler
Journal:  Science       Date:  1981-09-25       Impact factor: 47.728

5.  Calcium entry blockers and cardiovacular failure.

Authors:  P M Vanhoutte
Journal:  Fed Proc       Date:  1981-12

6.  Endothelial regeneration. II. Restitution of endothelial continuity.

Authors:  C C Haudenschild; S M Schwartz
Journal:  Lab Invest       Date:  1979-11       Impact factor: 5.662

7.  Calcium antagonists suppress atherogenesis in aorta but not in the intramural coronary arteries of cholesterol-fed rabbits.

Authors:  R Ginsburg; K Davis; M R Bristow; K McKennett; S R Kodsi; M E Billingham; J S Schroeder
Journal:  Lab Invest       Date:  1983-08       Impact factor: 5.662

8.  Role of endothelium and hypercholesterolemia in intimal thickening and lipid accumulation.

Authors:  C R Minick; M B Stemerman; W Insull
Journal:  Am J Pathol       Date:  1979-04       Impact factor: 4.307

9.  Inhibition of human platelet functions by verapamil.

Authors:  Y Ikeda; M Kikuchi; K Toyama; K Watanabe; Y Ando
Journal:  Thromb Haemost       Date:  1981-04-30       Impact factor: 5.249

10.  Does nifedipine suppress atherogenesis in WHHL rabbits?

Authors:  J L Van Niekerk; T Hendriks; H H De Boer; A Van 't Laar
Journal:  Atherosclerosis       Date:  1984-10       Impact factor: 5.162

View more
  11 in total

Review 1.  Antiatherogenic effects of calcium-channel blockers: possible mechanisms of action.

Authors:  P D Henry
Journal:  Cardiovasc Drugs Ther       Date:  1990-08       Impact factor: 3.727

2.  Retardation of coronary artery disease in humans by the calcium-channel blocker nifedipine: results of the INTACT study (International Nifedipine Trial on Antiatherosclerotic Therapy).

Authors:  P R Lichtlen; P G Hugenholtz; W Rafflenbeul; H Hecker; S Jost; P Nikutta; J W Deckers
Journal:  Cardiovasc Drugs Ther       Date:  1990-08       Impact factor: 3.727

Review 3.  Pharmacology of the calcium antagonist isradipine.

Authors:  U T Rüegg; R P Hof
Journal:  Drugs       Date:  1990       Impact factor: 9.546

4.  Reduction of intimal hyperplasia and enhanced reactivity of experimental vein bypass grafts with verapamil treatment.

Authors:  M N el-Sanadiki; K S Cross; J J Murray; R W Schuman; E Mikat; R L McCann; P O Hagen
Journal:  Ann Surg       Date:  1990-07       Impact factor: 12.969

5.  Inhibitory effect of clentiazem (TA-3090), a new calcium antagonist, on balloon catheter-induced intimal thickening of rabbit aorta.

Authors:  Y Saso; A Ohtani; A Odawara; H Iwasaki; K Takashima; T Morita
Journal:  Cardiovasc Drugs Ther       Date:  1993-04       Impact factor: 3.727

6.  Basic fibroblast growth factor enhances the coupling of intimal hyperplasia and proliferation of vasa vasorum in injured rat arteries.

Authors:  E R Edelman; M A Nugent; L T Smith; M J Karnovsky
Journal:  J Clin Invest       Date:  1992-02       Impact factor: 14.808

Review 7.  Can the coronary atherosclerotic process be influenced by calcium antagonists?

Authors:  G Kober; W Schneider; G Cieslinski; M Kaltenbach
Journal:  Drugs       Date:  1992       Impact factor: 9.546

Review 8.  Concept of an antiatherosclerotic efficacy of calcium entry blockers. INTACT Investigators.

Authors:  S Jost; W Rafflenbeul; J Deckers; B Wiese; H Hecker; P Nikutta; P Lippolt; P Lichtlen
Journal:  Eur J Epidemiol       Date:  1992-05       Impact factor: 8.082

Review 9.  Isradipine. An update of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the treatment of mild to moderate hypertension.

Authors:  R N Brogden; E M Sorkin
Journal:  Drugs       Date:  1995-04       Impact factor: 9.546

Review 10.  Calcium channel regulation in vascular smooth muscle cells: synergistic effects of statins and calcium channel blockers.

Authors:  Gerard F Clunn; Peter S Sever; Alun D Hughes
Journal:  Int J Cardiol       Date:  2009-06-11       Impact factor: 4.164

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.